vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($208.0M vs $180.9M, roughly 1.1× AVANOS MEDICAL, INC.). VIRTUS INVESTMENT PARTNERS, INC. runs the higher net margin — 16.3% vs -0.7%, a 17.0% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -10.9%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-74.1M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -3.2%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
AVNS vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $208.0M |
| Net Profit | $-1.3M | $33.9M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 19.1% |
| Net Margin | -0.7% | 16.3% |
| Revenue YoY | 0.7% | -10.9% |
| Net Profit YoY | 99.7% | -14.2% |
| EPS (diluted) | $-0.02 | $5.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $208.0M | ||
| Q3 25 | $177.8M | $216.4M | ||
| Q2 25 | $175.0M | $210.5M | ||
| Q1 25 | $167.5M | $217.9M | ||
| Q4 24 | $179.6M | $233.5M | ||
| Q3 24 | $170.4M | $227.0M | ||
| Q2 24 | $171.7M | $224.4M | ||
| Q1 24 | $166.1M | $222.0M |
| Q4 25 | $-1.3M | $33.9M | ||
| Q3 25 | $-1.4M | $31.3M | ||
| Q2 25 | $-76.8M | $42.7M | ||
| Q1 25 | $6.6M | $28.1M | ||
| Q4 24 | $-397.3M | $39.5M | ||
| Q3 24 | $4.3M | $49.1M | ||
| Q2 24 | $1.8M | $26.0M | ||
| Q1 24 | $-900.0K | $37.9M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 19.1% | ||
| Q3 25 | 0.1% | 21.7% | ||
| Q2 25 | -42.6% | 21.5% | ||
| Q1 25 | 6.1% | 16.8% | ||
| Q4 24 | -233.0% | 21.7% | ||
| Q3 24 | 7.0% | 24.3% | ||
| Q2 24 | 3.7% | 19.7% | ||
| Q1 24 | 2.4% | 14.5% |
| Q4 25 | -0.7% | 16.3% | ||
| Q3 25 | -0.8% | 14.5% | ||
| Q2 25 | -43.9% | 20.3% | ||
| Q1 25 | 3.9% | 12.9% | ||
| Q4 24 | -221.2% | 16.9% | ||
| Q3 24 | 2.5% | 21.6% | ||
| Q2 24 | 1.0% | 11.6% | ||
| Q1 24 | -0.5% | 17.1% |
| Q4 25 | $-0.02 | $5.15 | ||
| Q3 25 | $-0.03 | $4.65 | ||
| Q2 25 | $-1.66 | $6.12 | ||
| Q1 25 | $0.14 | $4.05 | ||
| Q4 24 | $-8.64 | $4.65 | ||
| Q3 24 | $0.09 | $5.71 | ||
| Q2 24 | $0.04 | $2.43 | ||
| Q1 24 | $-0.02 | $4.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | $390.0M |
| Stockholders' EquityBook value | $778.2M | $934.0M |
| Total Assets | $1.1B | $4.3B |
| Debt / EquityLower = less leverage | 0.12× | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | $390.0M | ||
| Q3 25 | $93.4M | $390.6M | ||
| Q2 25 | $95.7M | $231.3M | ||
| Q1 25 | $98.0M | $231.7M | ||
| Q4 24 | $125.3M | $232.1M | ||
| Q3 24 | $152.6M | $237.5M | ||
| Q2 24 | $164.9M | $247.6M | ||
| Q1 24 | $167.2M | $253.0M |
| Q4 25 | $778.2M | $934.0M | ||
| Q3 25 | $778.0M | $918.7M | ||
| Q2 25 | $776.3M | $896.4M | ||
| Q1 25 | $839.4M | $893.7M | ||
| Q4 24 | $828.5M | $897.5M | ||
| Q3 24 | $1.2B | $889.0M | ||
| Q2 24 | $1.2B | $868.7M | ||
| Q1 24 | $1.2B | $871.7M |
| Q4 25 | $1.1B | $4.3B | ||
| Q3 25 | $1.1B | $3.9B | ||
| Q2 25 | $1.0B | $3.7B | ||
| Q1 25 | $1.1B | $3.7B | ||
| Q4 24 | $1.2B | $4.0B | ||
| Q3 24 | $1.7B | $3.6B | ||
| Q2 24 | $1.7B | $3.6B | ||
| Q1 24 | $1.7B | $3.5B |
| Q4 25 | 0.12× | 0.42× | ||
| Q3 25 | 0.12× | 0.43× | ||
| Q2 25 | 0.12× | 0.26× | ||
| Q1 25 | 0.12× | 0.26× | ||
| Q4 24 | 0.15× | 0.26× | ||
| Q3 24 | 0.12× | 0.27× | ||
| Q2 24 | 0.13× | 0.29× | ||
| Q1 24 | 0.14× | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-67.2M |
| Free Cash FlowOCF − Capex | $21.3M | $-74.1M |
| FCF MarginFCF / Revenue | 11.8% | -35.6% |
| Capex IntensityCapex / Revenue | 3.8% | 3.3% |
| Cash ConversionOCF / Net Profit | — | -1.99× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $100.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-67.2M | ||
| Q3 25 | $14.0M | $108.3M | ||
| Q2 25 | $6.8M | $75.8M | ||
| Q1 25 | $25.7M | $-3.8M | ||
| Q4 24 | $57.9M | $1.8M | ||
| Q3 24 | $23.0M | $69.1M | ||
| Q2 24 | $27.8M | $70.0M | ||
| Q1 24 | $-8.0M | $-34.5M |
| Q4 25 | $21.3M | $-74.1M | ||
| Q3 25 | $7.0M | $106.9M | ||
| Q2 25 | $-4.2M | $74.2M | ||
| Q1 25 | $19.0M | $-6.8M | ||
| Q4 24 | $53.1M | $-3.8M | ||
| Q3 24 | $20.0M | $68.7M | ||
| Q2 24 | $21.9M | $68.6M | ||
| Q1 24 | $-12.1M | $-36.5M |
| Q4 25 | 11.8% | -35.6% | ||
| Q3 25 | 3.9% | 49.4% | ||
| Q2 25 | -2.4% | 35.2% | ||
| Q1 25 | 11.3% | -3.1% | ||
| Q4 24 | 29.6% | -1.6% | ||
| Q3 24 | 11.7% | 30.3% | ||
| Q2 24 | 12.8% | 30.6% | ||
| Q1 24 | -7.3% | -16.4% |
| Q4 25 | 3.8% | 3.3% | ||
| Q3 25 | 3.9% | 0.7% | ||
| Q2 25 | 6.3% | 0.7% | ||
| Q1 25 | 4.0% | 1.4% | ||
| Q4 24 | 2.7% | 2.4% | ||
| Q3 24 | 1.8% | 0.2% | ||
| Q2 24 | 3.4% | 0.6% | ||
| Q1 24 | 2.5% | 0.9% |
| Q4 25 | — | -1.99× | ||
| Q3 25 | — | 3.45× | ||
| Q2 25 | — | 1.77× | ||
| Q1 25 | 3.89× | -0.13× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | 5.35× | 1.41× | ||
| Q2 24 | 15.44× | 2.69× | ||
| Q1 24 | — | -0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
VRTS
| Open End Funds | $68.9M | 33% |
| Retail Separate Accounts | $51.3M | 25% |
| Institutional Accounts | $39.6M | 19% |
| Administration And Shareholder Service Fees | $18.4M | 9% |
| Closed End Funds | $15.9M | 8% |
| Distribution And Service Fees | $12.3M | 6% |
